8-K: Mineralys Therapeutics Adjusts Primary Endpoint for Hypertension Trial Following FDA Discussions

Mineralys Therapeutics is modifying the primary endpoint of its Advance-HTN trial to align with FDA feedback, focusing on a shorter timeframe for blood pressure assessment.

Summary

• Mineralys Therapeutics is conducting two pivotal clinical trials, Advance-HTN and Launch-HTN, to evaluate lorundrostat for treating uncontrolled or resistant hypertension.
• The Advance-HTN trial is a Phase 2 study with 261 participants, initially measuring changes in 24-hour ambulatory systolic blood pressure at 12 weeks.
• The Launch-HTN trial is a Phase 3 study with approximately 1,000 participants, initially measuring changes in office-measured systolic blood pressure at 12 weeks.
• Following discussions with the FDA, the primary endpoint for Launch-HTN was changed to assess automated office measured systolic blood pressure at 6 weeks, pooling results for subjects on 50 mg QD.
• Mineralys intends to implement a similar change for Advance-HTN, pending FDA alignment, revising the primary endpoint to change in 24-hour ambulatory blood pressure at 4 weeks, pooling results for subjects on 50 mg QD.
• All relevant efficacy measures will still be collected and analyzed at 12 weeks for both 50 mg QD and 100 mg QD groups in both trials.
• No other aspects of the trial designs or operational activities are being modified.

Sentiment

Score: 6

Explanation: The document indicates a necessary adjustment to the clinical trial design based on FDA feedback, which is a normal part of the drug development process. While there are risks associated with the development of lorundrostat, the company is actively working to address them. The sentiment is neutral to slightly positive.

Positives

• The change in primary endpoint for Advance-HTN could potentially accelerate the timeline for data analysis.
• Alignment with the FDA on trial endpoints may streamline the regulatory approval process.
• The company is still collecting and analyzing data at 12 weeks, providing a comprehensive view of the drug's efficacy.
• No other aspects of the trial designs or operational activities are being modified, minimizing disruption.

Negatives

• The change in primary endpoint for Advance-HTN may indicate a need to expedite data collection or address potential concerns raised by the FDA.
• The FDA may not support the proposed revision to the primary endpoint for the Advance-HTN trial.
• The company's future performance is entirely dependent on the success of lorundrostat.

Risks

• The FDA may not support the proposed revision to the primary endpoint for the Advance-HTN trial.
• The company's future performance is entirely dependent on the success of lorundrostat.
• There are potential delays in the commencement, enrollment, and completion of clinical trials.
• Later developments with the FDA may be inconsistent with the feedback from the completed end of Phase 2 meeting.
• The company is dependent on third parties for manufacturing, research, and clinical testing.
• Unexpected adverse side effects or inadequate efficacy of lorundrostat may limit its development.
• Unfavorable results from clinical trials and nonclinical studies are a risk.
• The company relies on an exclusive license with Mitsubishi Tanabe Pharma for intellectual property rights to lorundrostat.

Future Outlook

The company plans to continue the clinical development of lorundrostat, with topline data from the Advance-HTN trial expected in the fourth quarter of 2024 and from the Launch-HTN trial in the second half of 2025. The company also anticipates that aldosterone synthase inhibitors with an SGLT2 inhibitor may provide additive clinical benefits to patients.

Management Comments

• The company is working with the FDA to align on the primary endpoint for the Advance-HTN trial.
• The company believes that the Advance-HTN and Launch-HTN trials may serve as pivotal trials in any submission of a new drug application (NDA) to the FDA.

Industry Context

The modification of trial endpoints reflects the dynamic nature of drug development and the importance of aligning with regulatory agencies like the FDA. This change is not uncommon in clinical trials and is often a result of ongoing discussions and feedback from regulatory bodies. The focus on shorter timeframes for primary endpoints may be driven by a desire to accelerate the drug approval process.

Comparison to Industry Standards

• Changing primary endpoints mid-trial is not uncommon in the pharmaceutical industry, especially after discussions with regulatory bodies like the FDA.
• Many companies conducting Phase 2 and Phase 3 trials for hypertension treatments often adjust their protocols based on interim data and regulatory feedback.
• Companies like Novartis and AstraZeneca, which also have hypertension drug development programs, have similarly adjusted trial designs based on regulatory interactions.
• The shift to shorter primary endpoint timeframes, such as 4 weeks and 6 weeks, is becoming more common as companies seek to expedite the drug approval process.

Stakeholder Impact

• Shareholders may react to the change in primary endpoint and the potential impact on the timeline for drug approval.
• Patients with uncontrolled or resistant hypertension may benefit from the development of lorundrostat.
• Employees of Mineralys Therapeutics will continue to work on the clinical trials and drug development process.

Next Steps

• The company will seek alignment with the FDA on the revised primary endpoint for the Advance-HTN trial.
• The company will continue to enroll patients in the Launch-HTN trial.
• The company will analyze the data from both trials at 12 weeks.
• The company will prepare for the release of topline data from the Advance-HTN trial in the fourth quarter of 2024 and from the Launch-HTN trial in the second half of 2025.

Key Dates

Keywords

lorundrostat, hypertension, clinical trial, FDA, blood pressure, Advance-HTN, Launch-HTN, primary endpoint, pharmaceutical, drug development